A New Synthetic Peptide with In vitro Antibacterial Potential Against Escherichia coli O157:H7 and Methicillin-Resistant Staphylococcus aureus (MRSA).
In this work, we performed the rational design of a cationic antimicrobial peptide, GIBIMPY4, using the software DEPRAMPs developed at the GIBIM research group. GIBIMPY4 has a length of 17 amino acids, it is amphipathic, its structure is α-helix and it has a net charge of (+5). Solid-phase peptide synthesis was performed using the Fmoc strategy in acid medium. The primary structure was confirmed by MALDI-TOF mass spectrometry. The antimicrobial activity of the peptide was evaluated by broth microdilution method by measuring optical density in 96-well microplates. The minimal inhibitory concentration of GIBIMPY4 to kill 50 % of the bacterial cells (MIC50) was 6.20 ± 0.02 µM for MRSA and 4.55 ± 0.02 µM for E. coli O157:H7, while also reporting a bacteriostatic effect for the later. GIBIMPY4 activity was sensitive to salt concentration in E. coli but insignificant effect in its activity against MRSA. The peptide seems to be a broad-spectrum antimicrobial agent based on the results against Gram-positive and Gram-negative bacteria and was specific for bacterial cells E. coli O157:H7 with index of specificity equal to 9.01 in vitro assays.
Laboratorio de Espectroscopia Atómica y Molecular (LEAM), Escuela de Química, Universidad Industrial de Santander, Parque Tecnológico Guatiguará, Piedecuesta, 681012, Colombia. yuly.prada@correo.uis.edu.co.|Grupo de Investigación en Bioquímica y Microbiología (GIBIM), Escuela de Bacteriología, Universidad Industrial de Santander, Bucaramanga, 680002, Colombia. yuly.prada@correo.uis.edu.co.
Y A
YA
Prada
Núcleo de Biotecnología Curauma, Universidad Católica de Valparaíso, 2373223, Valparaiso, Chile.
F
F
Guzmán
Grupo de Investigación en Bioquímica y Microbiología (GIBIM), Escuela de Bacteriología, Universidad Industrial de Santander, Bucaramanga, 680002, Colombia.|Centro de Investigación en Enfermedades Tropicales (CINTROP), Escuela de Medicina, Universidad Industrial de Santander, Parque Tecnológico Guatiguará, Piedecuesta, 681012, Colombia.
P
P
Rondón
Centro de Investigación en Enfermedades Tropicales (CINTROP), Escuela de Medicina, Universidad Industrial de Santander, Parque Tecnológico Guatiguará, Piedecuesta, 681012, Colombia.
P
P
Escobar
Grupo de Investigación en Bioquímica y Microbiología (GIBIM), Escuela de Bacteriología, Universidad Industrial de Santander, Bucaramanga, 680002, Colombia.
C
C
Ortíz
Grupo de Investigación en Control, Electrónica, Modelado y Simulación (CEMOS), Escuela de Ingeniería Eléctrica, Electrónica y Telecomunicaciones, Universidad Industrial de Santander, Bucaramanga, 680002, Colombia.
D A
DA
Sierra
Grupo de Investigación en Bioquímica y Microbiología (GIBIM), Escuela de Bacteriología, Universidad Industrial de Santander, Bucaramanga, 680002, Colombia.
R
R
Torres
Laboratorio de Espectroscopia Atómica y Molecular (LEAM), Escuela de Química, Universidad Industrial de Santander, Parque Tecnológico Guatiguará, Piedecuesta, 681012, Colombia.
E
E
Mejía-Ospino
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D023181:Antimicrobial Cationic Peptides / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D019453:Escherichia coli O157 / Q000187:drug effects*; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects*; D008826:Microbial Sensitivity Tests
D000900:Anti-Bacterial Agents; D023181:Antimicrobial Cationic Peptides
Antimicrobial peptide; Design of AMPs; E. coli O157:H7; MRSA